Saiba
Company Details
Status: Private
Employees: 1-10
Location:
Pfäffikon, Switzerland
Type:
sample
Technology:
sample
sample
sample
About: With the effective control of infectious diseases in many parts of the world, chronic, often non-communicable diseases have become the single largest cause of death and disability.Treatment of such chronic diseases is expensive and often ineffective. There is therefore a major need for novel treatment modalities to prevent rather than treat chronic diseases and that are available at affordable costs.Inducing long-lived antibody responses by vaccination against endogenous molecules, which are normally targeted by monoclonal antibodies, represents a promising way to tackle this issue.Saiba GmbH uses virally shaped nanoparticles as a scaffold for the generation of tailor-made vaccines. The nanoparticle base of the vaccines tricks the immune system into believing to be under viral attack, causing a strong immune response against the displayed antigen.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Saiba | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.